187 related articles for article (PubMed ID: 25152400)
1. Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment.
Knake C; Stamp L; Bahn A
Biochem Biophys Res Commun; 2014 Sep; 452(1):157-62. PubMed ID: 25152400
[TBL] [Abstract][Full Text] [Related]
2. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
[TBL] [Abstract][Full Text] [Related]
3. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
[TBL] [Abstract][Full Text] [Related]
5. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
6. Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.
Stamp LK; Merriman TR; Barclay ML; Singh JA; Roberts RL; Wright DF; Dalbeth N
Semin Arthritis Rheum; 2014 Oct; 44(2):170-4. PubMed ID: 24925693
[TBL] [Abstract][Full Text] [Related]
7. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
Stamp LK; Turner R; Khalilova IS; Zhang M; Drake J; Forbes LV; Kettle AJ
Rheumatology (Oxford); 2014 Nov; 53(11):1958-65. PubMed ID: 24899662
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
Stocker SL; Graham GG; McLachlan AJ; Williams KM; Day RO
J Rheumatol; 2011 May; 38(5):904-10. PubMed ID: 21285173
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
10. Oxipurinol: alloxanthine, Oxyprim, oxypurinol.
Drugs R D; 2004; 5(3):171-5. PubMed ID: 15139781
[TBL] [Abstract][Full Text] [Related]
11. Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry.
Stocker SL; Franklin ME; Anderson JM; Pillans PI; Williams KM; McLachlan AJ; Day RO; Taylor PJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Sep; 878(25):2363-8. PubMed ID: 20702150
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation.
Orriss IR; Arnett TR; George J; Witham MD
Exp Cell Res; 2016 Mar; 342(2):166-74. PubMed ID: 26968635
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
Wen YF; Brundage RC; Roman YM; Culhane-Pera KA; Straka RJ
Br J Clin Pharmacol; 2023 Oct; 89(10):2964-2976. PubMed ID: 37202871
[TBL] [Abstract][Full Text] [Related]
14. Effect of furosemide on renal excretion of oxypurinol and purine bases.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
Metabolism; 2001 Feb; 50(2):241-5. PubMed ID: 11229436
[TBL] [Abstract][Full Text] [Related]
15. Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats.
Tayama Y; Sugihara K; Sanoh S; Miyake K; Kitamura S; Ohta S
J Pharm Health Care Sci; 2022 Dec; 8(1):31. PubMed ID: 36476607
[TBL] [Abstract][Full Text] [Related]
16. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Stamp L; Gow P; Sharples K; Raill B
Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
[TBL] [Abstract][Full Text] [Related]
17. Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy.
Chung Y; Stocker SL; Graham GG; Day RO
Am J Med Sci; 2008 Mar; 335(3):219-26. PubMed ID: 18344696
[TBL] [Abstract][Full Text] [Related]
18. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Chu WY; Annink KV; Nijstad AL; Maiwald CA; Schroth M; Bakkali LE; van Bel F; Benders MJNL; van Weissenbruch MM; Hagen A; Franz AR; Dorlo TPC; Allegaert K; Huitema ADR;
Clin Pharmacokinet; 2022 Feb; 61(2):321-333. PubMed ID: 34617261
[TBL] [Abstract][Full Text] [Related]
20. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
